University of Nottingham Medical School, Derby City General Hospital, UK.
Am J Surg. 2010 Aug;200(2):197-203. doi: 10.1016/j.amjsurg.2009.08.041. Epub 2010 Feb 1.
The objective of this study was to investigate whether the preoperative hematologic markers, the platelet-lymphocyte ratio (PLR), or the neutrophil-lymphocyte ratio (NLR) ratio are significant prognostic indicators in resected pancreatic ductal adenocarcinoma.
A total of 84 patients undergoing pancreatoduodenectomy for pancreatic ductal adenocarcinoma over a 10-year period were identified from a retrospectively maintained database.
The preoperative NLR was found to be a significant prognostic marker (P = .023), whereas PLR had no significant relationship with survival (P = .642) using univariate Cox survival analysis. The median overall survival in patients with an NLR of < or =3.0 (n = 55) was 13.7, 17.0 months in those with an NLR of 3.0 to 4.0 (n = 17) and 5.9 months in patients with a value of >4.0 (n = 12) (log rank, P = .016). The NLR retained its significance on multivariate analysis (P = .039) along with resection margin status (P = .001).
The preoperative NLR represents a significant independent prognostic indicator in patients with resected pancreatic ductal adenocarcinoma, whereas PLR does not.
本研究旨在探讨术前血液学标志物血小板-淋巴细胞比值（PLR）或中性粒细胞-淋巴细胞比值（NLR）是否是可切除胰腺导管腺癌的重要预后指标。
从一个回顾性维护的数据库中确定了在过去 10 年中接受胰十二指肠切除术治疗胰腺导管腺癌的 84 例患者。
单因素 Cox 生存分析显示，术前 NLR 是一个显著的预后标志物（P =.023），而 PLR 与生存无显著关系（P =.642）。NLR<或=3.0（n = 55）的患者的中位总生存期为 13.7 个月，NLR 为 3.0-4.0（n = 17）的患者为 17.0 个月，NLR>4.0（n = 12）的患者为 5.9 个月（对数秩检验，P =.016）。NLR 在多因素分析中仍然具有显著性（P =.039），与切缘状态（P =.001）一起成为独立的预后指标。
术前 NLR 是可切除胰腺导管腺癌患者的一个显著独立预后指标，而 PLR 则不是。
